Healthcare - Biotechnology - NASDAQ - US
$ 28.39
-6.33 %
$ 2.85 B
Market Cap
-7.93
P/E
CASH FLOW STATEMENT
-188 M
OPERATING CASH FLOW
83.3 M
INVESTING CASH FLOW
54.3 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Dyne Therapeutics, Inc.
| Net Income | -236 M |
| Depreciation & Amortization | 571 K |
| Capital Expenditures | -729 K |
| Stock-Based Compensation | 20 M |
| Change in Working Capital | 26.3 M |
| Others | 4.27 M |
| Free Cash Flow | -189 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||||||
| Net Income | (235.9) | (168.1) | (149.3) | (59.4) | (14.9) | (4.8) | 76.0 | (1 240.0) | 50.0 | (67.0) | (356.0) | 87.0 | (1 645.0) | (234.0) | (1 262.0) | 174.0 | 264.0 |
| Depreciation & Amortization | 0.6 | 1.7 | 1.1 | 0.7 | 0.3 | 24 K | 867.0 | 766.0 | 614.0 | 292.0 | 467.0 | 26.0 | 346.0 | 408.0 | 359.0 | 376.0 | 333.0 |
| Deferred Income Tax | 0 | 0 | 2.6 | 12 K | 0 | 0 | 610.0 | 45.0 | 477.0 | 1.0 | 56.0 | 0 | 632.0 | 195.0 | (436.0) | 73.0 | 215.0 |
| Stock Based Compensation | 20.0 | 15.2 | 17.5 | 6.6 | 26 K | 1 K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Operating Activities | 0.9 | 3.0 | (0.7) | 0.5 | 1.3 | 21 K | 584.0 | 136.0 | (215.0) | (1 336.0) | (275.0) | (340.0) | 813.0 | (434.0) | 2 384.0 | (741.0) | (471.0) |
| Change in Working Capital | 26.3 | (5.4) | 9.3 | 5.1 | 1.4 | 0.6 | (1 596.0) | 938.0 | (860.0) | 1 029.0 | 268.0 | 183.0 | (166.0) | 488.0 | (910.0) | 437.0 | 522.0 |
| Cash From Operations | (188.2) | (153.6) | (119.6) | (46.5) | (11.8) | (4.2) | 585.0 | 676.0 | 94.0 | (62.0) | 175.0 | (44.0) | (20.0) | 423.0 | 135.0 | 319.0 | 341.0 |
| INVESTING CASH FLOW | |||||||||||||||||
| Capital Expenditures | (0.7) | (3.1) | (3.6) | (1.2) | (1.6) | (0.1) | (224.0) | (326.0) | (275.0) | 0 | (98.0) | 0 | (242.0) | (333.0) | 0 | 0 | 0 |
| Other Items | 84.0 | 90.3 | (134.3) | (44.5) | 0 | 0 | (2 535.0) | (1 821.0) | (919.0) | (5 148.0) | 572.0 | 348.0 | (12.0) | (201.0) | 251.0 | (102.0) | (817.0) |
| Cash From Investing Activities | 83.3 | 87.2 | (137.9) | (45.7) | (1.6) | (0.1) | (2 759.0) | (2 147.0) | (1 194.0) | (5 148.0) | 474.0 | 348.0 | (254.0) | (534.0) | 251.0 | (102.0) | (817.0) |
| FINANCING CASH FLOW | |||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (250.0) | (1 870.0) | (843.0) | (348.0) | (396.0) | (291.0) | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 64 K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.0 | 0.5 | 0.6 | 134.4 | 20.0 | 12.4 | (1 299.0) | 2 742.0 | (265.0) | 5 210.0 | (154.0) | (328.0) | 379.0 | (69.0) | (608.0) | 148.0 | 433.0 |
| Cash From Financing Activities | 54.3 | 37.4 | 157.8 | 380.7 | 20.0 | 12.4 | (1 299.0) | 2 742.0 | (265.0) | 5 210.0 | (154.0) | (328.0) | 379.0 | (69.0) | (608.0) | 148.0 | 433.0 |
| CHANGE IN CASH | |||||||||||||||||
| Net Change In Cash | (50.5) | (29.1) | (99.6) | 288.5 | 6.5 | 12.4 | (3 473.0) | 1 271.0 | (1 365.0) | 0 | 495.0 | (107.0) | 105.0 | (180.0) | (222.0) | 365.0 | (43.0) |
| FREE CASH FLOW | |||||||||||||||||
| Free Cash Flow | (188.9) | (156.7) | (123.2) | (47.7) | (13.5) | (4.3) | 361.0 | 350.0 | (181.0) | (62.0) | 77.0 | (44.0) | (262.0) | 90.0 | 135.0 | 319.0 | 341.0 |